BDKRB2 and atherosclerosis: Then, intact kinins bind to bradykinin B2 receptors activating signaling pathways such as NO-cyclic 3′,5′-guanosine monophosphate and prostacyclin–cyclic adenosine monophosphate, which trigger a broad spectrum of biological effects including vasodilatation, smooth muscle contraction and relaxation, inhibition of apoptosis, atherosclerosis, inflammation, hypertrophy and fibrosis, protection against ischemia/reperfusion damage and promotion of angiogenesis and neurogenesis [13].